Work

PI3K/AKT pathway deleterious mutations in lethal prostate cancer

Year: 2018

Type: article

Study design: Observational Study

Abstract: Background: PI3K/AKT signaling is commonly hijacked in prostate cancer (PC), associating with poorer prognosis and worse response to next generation hormonal treatment (NGHT) including abiraterone and enzalutamide. We studied deleterious pathway mutations in metastatic castration resistant PC (mCRPC) patients correlating these to prognosis and response to NGHT in a case-control study.

Source: Annals of Oncology

DOI: 10.1093/annonc/mdy284.047

Authors: P. Rescigno, M. Rediti, D. Dolling, D.N. Rodrigues, D. Bianchini, R. Riisnaes, C. Messina, M. Barrero, A. Petremolo, A. Sharp, S. Sumanasuriya, G. Seed, I. Figueiredo, S. Miranda, J. Goodall, J. Mateo, R. Chandler, W. Yuan, S. Carreira, J.S. de Bono

Institutions: Institute of Cancer Research, Royal Marsden Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,080

OpenAlex ID: W2898350824

FWCI: 0.571

Cites:

Cited by: 4

Related to: 10